Tobias Boch

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Renal Cell Carcinoma

Coronary Artery Disease

Low Density Lipoprotein

Top Venues

Clinical drug investigation

Cardiovascular drugs and therapy

European journal of cancer care

American journal of cardiovascular drugs : drugs, devices, and other interventions

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Tobias Boch, Julia Caroline Michaeli
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch, Thomas Michaeli
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovascular drugs and therapy (2022)
Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli
Socio-economic burden of disease: Survivorship costs for renal cell carcinoma. European journal of cancer care 31 (3) (2022)
Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Clinical drug investigation 42 (8) (2022)
Vladimir Riabov, Maximilian Mossner, Alexandra Stöhr, Johann-Christoph Jann, Alexander Streuer, Nanni Schmitt, Antje Knaflic, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Christiane Schumann, Claudia D Baldus, Torsten J Schulze, Patrick Wuchter, Henning Röhl, Ahmed Jawhar, Christel Weiss, Tobias Boch, Georgia Metzgeroth, Martin Neumann, Wolf-Karsten Hofmann, Florian Nolte, Daniel Nowak
High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes. British journal of haematology 192 (5) (2021)